Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 104

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 104
---
    75,000 |     |                                                                                         | - |     | $                   | 1.16 |     | 3/25/34         |     |                                                      |       - |     |                                                            |       - |     |                                                                                                  | - |     |                                                                                                                  | - |
|          |     |                                                              |         - |     |                                                                |   150,000 |     |                                                                                         | - |     | $                   | 1.19 |     | 12/6/34         |     |                                                      |       - |     |                                                            |       - |     |                                                                                                  | - |     |                                                                                                                  | - |

| 58 |

Option Exercises and Stock Vested

No stock options were exercised by our executive officers during the year ended December 31, 2024.

<div align='center'>EXECUTIVE OFFICERS</div>

| Name            |     | Age |     | Position                       |
| Erez            
 Aminov          |     |  47 |     | Chief                          
 Executive Officer and Chairman |
| Alan            
 Weichselbaum(1) |     |  61 |     | Chief                          
 Financial Officer              |

| (1) | Effective                                                                               
 May 16, 2025 Alan Weichselbaum was appointed as Chief Executive Officer of the Company. |

The following is certain biographical information describing the business experience of our executive officers as of the date of this filing who do not serve as directors. The biographies of Mr. Aminov appeared earlier in this proxy statement. See “Proposal 2. Election of Directors.”

Alan Weichselbaum, CPA, MBA, 61, Chief Financial Officer of the Company since May 2025, brings over 30 years of experience in corporate finance, capital markets, and strategic advisory across multiple industries. He plays a key leadership role in advancing the financial and strategic objectives of both companies as they pursue growth through drug development, licensing, and potential M&A opportunities. Mr. Weichselbaum has served as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. since May 2025. Additionally, since 2015, Mr. Weichselbaum has served as a director of FinWise Bancorp (Nasdaq: FINW), providing oversight and strategic direction to the publicly traded financial institution. In 2011, he founded The Wexus Group, an outsourced CFO advisory firm that partners with small and mid-sized companies to support growth, capital structuring